• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
biocrates kits and pipettes

Bruker Acquires biocrates, a Leader in Quantitative Metabolomics

Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. Biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide.

Read more →
RECIPE kits for clinical laboratories

Bruker Applied MS Unveils Launches timsMetabo™ for PFAS Detection, and Highlights DART Advances for TDM and DoA

Bruker Corporation announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.

Read more →
STEMCELL Technologies

STEMCELL Technologies Announces Acquisition of Cellular Highways

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.

Read more →
Glutathione

Eden Expands Access to Glutathione Injection Protocols via Independent Licensed Providers and Pharmacies

Eden, the leading health platform connecting individuals with licensed providers and pharmacies focused on metabolic health, announced expanded access to a pharmacy-grade compounded glutathione injection protocol. The therapy is now available for eligible individuals in most states through Eden's network of licensed providers and pharmacies.

Read more →
Merck

Merck’s Phase 3 KEYNOTE-B96 trial met its PFS endpoint in platinum-resistant ovarian cancer, both in PD-L1–positive and all patients

Merck known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.

Read more →
RizaFilm® Packaging by Gensco® Pharma

Gensco Pharma® acquires global rights and intellectual property for RizaFilm® and RizaPort®

Gensco Laboratories LLC d/b/a Gensco Pharma, a leader in specialty pharmaceuticals, proudly announces the acquisition of the global rights and intellectual property for the first and only rizatriptan Oral Dissolvable Film (ODF), which was co-developed under the trade names RizaFilm in the U.S. and both RizaFilm and RizaPort globally.

Read more →
BrightFocus Foundation

Nearly $13M in funding is awarded by the BrightFocus Foundation to 50 scientists for research on Alzheimer's, macular degeneration, and glaucoma

Private research nonprofit BrightFocus Foundation announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma. This includes $7.3 million to its Alzheimer’s Disease Research program, $3.8 million to its Macular Degeneration Research program, and $1.8 million to its National Glaucoma Research program.

Read more →
Pete Buzy

NewSpring Capital and Kineticos Life Sciences lead a $22 million investment in Kincell Bio, a cell therapy CDMO, and appoint industry veteran Pete Buzy to the board of directors

Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, which invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies.

Read more →
Terumo Neuro: SOFIA™ 88 Neurovascular Support Catheter

Terumo Neuro Expands Stroke Legacy with US Commercial Launch of the SOFIA™ 88 Neurovascular Support Catheter

Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, announced the commercial availability of the SOFIA™ 88 Neurovascular Support Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™ Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade.

Read more →